

Vaccine Upstream Processing – an overview DCVMN 10 March 2017

Dr. Mats Lundgren, GE Healthcare Life Sciences

Confidential. Not to be copied, distributed, or reproduced without prior approval.

Outline of presentation

- Cell substrates for virus production
- Processing overview batch, fed-batch, perfusion
- Cell culture using Microcarriers
- Scale up of Microcarrier cultures
- Conclusions



Cell substrates for virus production



Confidential. Not to be copied, distributed, or reproduced without prior approval.

Diversification of technology – low efficiency



Selecting a cell line for virus production

- Cell substrate evolution from primary to diploid to continuous cell lines...
- Modern options: Vero, MDCK, EBx[™], AGE, PER.C6[™] ...
- Requirements
- Suitable for GMP production
- Good safety track record
- Good virus propagation
- Broadly and highly permissive
- Scalable to high volume production





Vero cells

- Accepted by regulatory authorities for viral vaccine production
- Used for production of live attenuated viral vaccines
- Long track record for production of polio and rabies vaccine
- The cell line was derived in 1962 from kidney epithelial cells of the African Green Monkey
- Available from ATCC at passage level 121
- Most vaccine manufacture is performed with cells at passage levels in the 130's or 140's
- Non-tumorigenic at vaccine production passage levels
- Anchorage dependent, can be expanded on Cytodex[™] microcarries



MDCK and Vero cells

	MDCK	Vero
+	Higher productivity Technically easier Less risk for propagation of adventitious viruses	Platform cell line (can be used for several virus vaccines) Good safety record Used for several marketed vaccines
-	Potential tumorigenicity/ oncogenicity New cell substrate Restricted to influenza	Lower productivity Technically challenging Potential propagation of adventitious viruses



Processing overview batch, fed-batch, perfusion



Confidential. Not to be copied, distributed, or reproduced without prior approval.

All culture systems have certain needs in common



- Absence of a competing organism
- Suitable temperature
- Suitable pH
- Suitable osmolality
- Well-mixed environment
- Gas transfer
- Not too much shear
- Nutrients to consume



A bioreactor provides a well-controlled environment to meet these needs

Online measurement and control of: Temp Agitation PH dO_2 dCO_2 CO_2 and Air/O₂ Sparge

Bioreactors may also have the ability to measure and control glucose concentration, as well as to measure biomass (viable cell density)

Confidential. Not to be copied, distributed, or reproduced without prior approval.

Overlay



What factors contribute to batch failure?

Nutrient depletion

• Cells have nothing left to "eat" (i.e., glucose, essential amino acids, vitamins)

Accumulation of toxic metabolites

• Could be inhibitory to cell growth or protein production

Shear sensitivity of the cells

- Cell death, or lysis that releases HCP and other "garbage" into media
- Often advisable to stop batch and purify a "cleaner" harvest stream before too much viability drop and cell lysis

Contamination

Loss of stability of production clone

Cells do not produce product anymore; sometimes seen with increasing generations

HCP = host cell protein



Batch process—all nutrients added into base medium along with inoculum at start of batch



Process duration ~ 3-4 d seed cultures

A high cell/product density is challenging to reach—osmolality constraints, because nutrients are added at start



Confidential. Not to be copied, distributed, or reproduced without prior approval.

Fed-batch process—concentrated nutrients added over time as cells grow





Confidential. Not to be copied, distributed, or reproduced without prior approval.

Fed-batch process—feeding over time allows stable nutrient concentration



Perfusion—rate is in vessel volumes per day (VVD) Reactor volume remains stable



GE)

Confidential. Not to be copied, distributed, or reproduced without prior approval.

Summary of batch, fed-batch, and perfusion processing for product manufacture





Confidential. Not to be copied, distributed, or reproduced without prior approval.

Bioreactors – Fixed vs Disposabled

Control and scalability





Presentation Title

Confidential. Not to be copied, distributed, or reproduced without prior approval.

Cell culture using Microcarriers



Confidential. Not to be copied, distributed, or reproduced without prior approval.

Scale up of adherent cell cultures

Increase volume



Increase number of units



Genetic Engineering News, 2007

One 2500 L bioreactor with a carrier concentration of 3 g/L (Cytodex[™] 1) provides the same surface area as 40 000 roller bottles (850 cm²/bottle)



Presentation Title

Why Microcarriers in vaccine production?



- Necessary for adherent cell lines
- Proven scalable technology (1000's of L)
- Large volume to surface ratio (less waste problem)
- Cost effective surface supply/m2
- Separates cells from secreted products
- Microporous carriers allow polarization & differentiation
- Increased productivity of functional

product



Presentation Title

Confidential. Not to be copied, distributed, or reproduced without prior approval.

Cytodex[™] specifications

	Cytodex 1	Cytodex 3
Matrix	Sephadex™	Sephadex
Particle diameter (µm)	200	175
Effective surface area (m²/g dry)	0.44	0.27
Relative density	1.03	1.04
Swelling volume (mL/g dry weight)	18	14
Surface modification	DEAE	Gelatine





Confidential. Not to be copied, distributed, or reproduced without prior approval.

Introduction to Cytodex[™] 1 and 3 Gamma

• Delivered gamma sterilized and ready to use. Supplied dry to save storage space and facilitate transportation.

Conventional process:





Confidential. Not to be copied, distributed, or reproduced without prior approval.

Viruses produced in microcarrier cultures

- Adenovirus
- Bovine rhinotrachteritis
- Endogenous C type
- Equine rhinopneumonitis
- Foot and mouth
- Group B arboviruses
- HAV
- Herpes
- Influenza

- Japaneese encephalitis
- Marek's
- Papova virus
- Polio
- Polyoma
- Pseudorabies
- Rabies
- RSV
- Rous sarcoma

- Rubella
- Sendai
- SV40
- Sindbis
- Small pox
- Vaccinia
- Vesicular stomatitis



Cell culture media and serum



Confidential. Not to be copied, distributed, or reproduced without prior approval.



Cell culture media and serum

- Serum Ensure quality, traceability and origin
- Classical media
- Animal origin free media
- Complex media containing hydrolysates
- Chemically defined media







The effect of cell culture media

Medium 1

Medium 2

Medium 3









Presentation Title

Confidential. Not to be copied, distributed, or reproduced without prior approval.

Serum-free expansion of Vero cells





Presentation Title

Confidential. Not to be copied, distributed, or reproduced without prior approval.

The effect of medium supplementation

-Supplement

+Supplement

Comparison









Presentation Title

Confidential. Not to be copied, distributed, or reproduced without prior approval.

Scale up of microcarrier cultures



Confidential. Not to be copied, distributed, or reproduced without prior approval.

Subcultivation – Scale up

Procedure

- Wash culture
- Add Trypsin. Optimal concentration and time of incubation need to be tested
- Inhibit trypsin when 90% of cells are detached
- Easy Cytodex[™] retention by using 100µm stainless steel sieve





Presentation Title

Confidential. Not to be copied, distributed, or reproduced without prior approval.





Confidential. Not to be copied, distributed, or reproduced without prior approval.

Change in workflow with presterilized microcarriers



Confidential. Not to be copied, distributed, or reproduced without prior approval. 29203492 AA | April 2016 33

Propagation of virus



Confidential. Not to be copied, distributed, or reproduced without prior approval.

Cell Culture

Cell line:		
Cell culture media:		
Medium supplements:		
Microcarrier:		
Cell detatchment:		

Vero (ATCC-CCL81) DMEM/Hams F-12 5% FCS, 0.2% Soy peptone, 0.2% Pluronic F-68 Cytodex[™] 1 at 3 g/L Trypsin

Influenza A/Solomon Island/3/2006(H1N1) 0.004

Equipment: Cell factory, 2 layers, 10 layers WAVE Bioreactor™ system 20/50 WAVE Bioreactor system 200





Virus: MOI:



Cell Growth

- Cell growth in seed and production reactor
- Upstream process in disposable bioreactors
- Procedure for bead to bead scale-up
- Comparable cell growth rate at 10 L and 50 L scale





Cell Metabolism

Depletion of glucose and glutamine prevented by medium exchange





Presentation Title

Confidential. Not to be copied, distributed, or reproduced without prior approval.

Virus growth kinetics

HA concentration and virus titer during culture

Cytopathic effect at harvest





- HA concentration at harvest was close to 12 µg/mL
- ViroCyt[™] virus counter data correlates well with TCID₅₀



Presentation Title

Confidential. Not to be copied, distributed, or reproduced without prior approval.

Thank you!

- www.gelifesciences.com
- GE, imagination at work and GE monogram are trademarks of General Electric Company.
- Cytodex, HyClone and WAVE Bioreactor are trademarks of GE Healthcare Company or one of its subsidiaries.
- © 2017 General Electric Company All rights reserved. First published Apr. 2013.
- All goods and services are sold subject to the terms and conditions of sale of the company within GE Healthcare which supplies them. A copy of these terms and conditions is available on request. Contact your local GE Healthcare representative for the most current information.
- GE Healthcare Bio-Sciences AB
- Björkgatan 30
- 751 84 Uppsala
- Sweden



